With autism prevalence now reaching 1 in 31 children in the United States according to the latest CDC data, the pressure on ...

Get all latest & breaking news on Chandrayaan 2. Watch videos, top stories and articles on Chandrayaan 2 at moneycontrol.com.

BACKGROUND: Medically tailored meals (MTM) have unanswered implementation questions. Providing MTM for a specific individual, ...

Space agency is targeting Wednesday for the historic journey-its first to the moon in more than half a century.

A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had ...

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...

- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated ...

The RELIEVE trial assesses remibrutinib's efficacy and safety in generalized myasthenia gravis, involving 180 participants in a 6-month double-blind study. Remibrutinib has shown a positive safety ...

November 6, 2025—Venova Medical announced the enrollment of the first patients in the VENOS-3 pivotal study of the company’s Velocity percutaneous arteriovenous fistulas (pAVF) system. According to ...

Panelists discuss how the GALAXI-2 and GALAXI-3 trials represented a landmark study design for Crohn’s disease research through their rigorous triple-dummy active comparator methodology, treat-through ...